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STENTLESS PORCINE 
AORTIC ROOT: VALVE OF 
CHOICE FOR THE ELDERLY 
PATIENT WITH SMALL 
AORTIC ROOT? 
The Medtronic Freestyle bioprosthesis is a stentless porcine aortic root cross-linked 
in dilute glutaraldehyde solution with stress-free fixation for the valve leaflets. It has 
been treated by a process in which amino oleic acid is used to reduce the potential 
for calcification. As a complete aortic root, it has the same versatility as the aortic 
homograft but has the advantage that it is readily available in all sizes to the 
implanting surgeon. Between January 1993 and May 1994, we implanted 64 
Freestyle bioprostheses as ortic valve replacements using a freehand technique; 5 
size 19 mm, 15 size 21 mm, 16 size 23 mm, 13 size 25 mm, and 15 size 27 mm valves 
were used. There were 35 men and the mean age was 75.7 years (64 to 84 years). The 
operative mortality was 3.1% (2/64). Echocardiograms at the time of discharge 
revealed mean aortic valve gradients ranging from 18.2 mm Hg for 19 mm to 10.3 
mm Hg for 27 mm valves. Etfective orifice areas ranged from 1.0 cm 2 for 19 mm to 
2.0 cm 2 for 27 mm valves. No patient had more than trace aortic insufliciency. Our 
early experience with this new stentless bioprosthesis hows it to have excellent 
hemodynamics especially in the smaller valve sizes. Using this valve in patients who 
have a small aortic root and require a tissue valve avoids the need for aortic root 
enlargement procedures. (J THORAC CARDIOVASC SURG 1995;109:871-6) 
Colleen F. Sintek, MD, Alden D. Fletcher, MD, PhD, and Siavosh Khonsari, MD, 
Los Angeles, Calif 
D espite more than 30 years of research and clin- 
ical applications, the pursuit for the ideal heart 
valve substitute continues. In the aortic position, the 
pulmonary autograft may come close to meeting 
all of the criteria for a perfect replacement valve; 
however, the operation does require prosthetic re- 
placement of the pulmonary valve and right ventric- 
ular outflow tract. Certainly the mechanical valves 
with their requirement for anticoagulation and 
thromboembolic complications are rar from ideal 
and the stented bioprostheses have inferior hemo- 
dynamics, especially in the smaller valve sizes. 1 
Homograft valves have been relatively durable and 
free of thromboembolic problems; however, in the 
United States their availability is limited. The stent- 
less porcine aortic root appears to be a good alter- 
native to the aortic homograft in terms of its hemo- 
dynamics. Like the homograft, the porcine aortic 
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root has no stent or sewing ring to obstruct forward 
flow. It is also believed that the nonstented porcine 
valve offers the potential for increased durability 
because of the elimination of the stent. Maintaining 
the structure of the native coronary sinuses may 
decrease the mechanical stress on the leaflets by 
dissipation of energy to the aortic root during 
closure at high back pressures. 
Patients and methods 
The device. The Freestyle aortic root is manufactured 
by Medtronic Heart Valves, Irvine, California. The leaf- 
lets are maintained at zero differential pressure during the 
glutaraldehyde flxation process. The aortic wall is fixed at 
40 mm Hg pressure to control the shrinkage of the wall 
and to maintain the natural symmetry of the commissure 
attachments to the aortic wall, which minimizes the po- 
tential for misalignment during implantation. The inflow 
aspect of the valve is covered with a single sheet of Dacron 
polyester, which extends over the myocardium to provide 
strength to his portion of the bioprosthesis. The right and 
left coronary arteries are ligated with 5 to 6 mm remnants 
that can be used in reimplantation f the patient's coro- 
nary arteries when the Freestyle valve is used for root 
replacement. The Freestyle valve is treated with an 
a-amino derivative of oleic acid, which has been shown in 
animal studies to mitigate leaflet calcification. Because 
calcification of valve leaflets is a major cause for failure of 
porcine bioprostheses, 2'3 this antimineralization treat- 
ment may lead to increased urability of the Freestyle 
aortic root. 
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Table I. Patient demographics and clinical 
parameters 
Mean Range 
Total patients 64 
Male gender 35 
Age (yr) 75.7 64-84 
AS 25 
AI 4 
Combined AS and AI 35 
Redo sternotomy 10 
Concomitant CABG 26 
Average crossclamp time (min) 
Isolated AVR 89.3 73-112 
With CABG 111.5 75-141 
Mean postop, length of stay (days) 12.7 6-48 
AS, Aortic stenosis; AI, aortic insufficiency; CABG, coronary artery bypass 
grafting; AVR, aortic valve replacement. 
Patients. Our institution is one of the study centers in 
the United States for the Medtronie Freestyle aortic root 
bioprosthesis. The clinical study is being conducted at 
multiple centers with all sites using a common investiga- 
tional plan. Before initiation of the use of the Freestyle 
valve at out hospital, the study design was approved by our 
institution's investigational review board. All patients 
believed to be candidates for bioprosthetic aortic valve 
replacement were considered for the Freestyle valve. 
Patients requiring multiple valve procedures were ex- 
cluded. Written informed consent was obtained from each 
patient before the operation. 
Surgical technique. Surgical technique consisted of 
standard cardiopulmonary bypäss with a single dual- 
staged venous cannula. Myocardial protection was 
achieved with moderate systemic hypothermia with ante- 
grade and retrograde cold blood cardioplegia. All patients 
underwent implantation of the Freestyle bioprosthesis a  
an aortic valve replacement by means of a freehand 
technique similar to that used by many for valve replace- 
ment with a homograft. An oblique aortotomy was made 
extending into the noncoronary sinus. The appropriate 
valve size was selected after the native aortic valve had 
been excised and the anulus debrided. A deliberate ffort 
was made to avoid undersizing the valve. In fact, the valve 
usually was oversized slightly on the basis of the patient's 
anulus size. We constructed the proximal suture line with 
interrupted 4-0 Ti-Cron sutures (Davis W. Geck, Dan- 
bury, Conn.) in a simple fashion, placing these stitches in 
the valve "anulus" first beneath the nadir of each sinus, 
plaeing the sutures approximately 2 mm apart, and picking 
up ventricular muscle and subaortic urtain to form a 
circle of stitches in a single plane. These sutures were 
brought up through the Dacron skirt of the Freestyle 
valve, which was then lowered into place, and the sutures 
were secured. The left and right coronary sinus portions of 
the Freestyle valve were removed, leaving a 3 to 4 mm 
scalloped rim of tissue except over the uppermost aspect 
of the commissures, where the rim was 5 to 6 mm. The 
noncoronary sinus portion of the Freestyle valve was left 
intact. Great care was taken to align the commissures of
the Freestyle valve at 120 degrees and to resuspend them 
at least 2 to 3 mm above the native commissures. This was 
accomplished with pledget-supported 4-0Prolene sutures 
(Ethicon, Inc., Somerville, N.J.), which were left untied. 
The distal suture line was completed with running 4-0 
Prolene suture, attaching the scalloped portions of the left 
and right coronary sinuses beneath the patient's coronary 
ostia and attaching the retained noncoronary portion of 
the Freestyle valve to the patient's aortic wall. The 
pledget-supported commissure sutures were then secured. 
Study methods. All patients underwent preoperative 
echocardiograms, intraoperative transesophageal echo- 
cardiographic evaluation of the left ventricular outflow 
tract and aortic valve function, as well as a transthoracic 
echocardiogram at the time of hospital discharge, 3 to 6 
months after the operation, and again 1 year after hospital 
discharge. From the echocardiogram, ean aortic valve 
gradient, cardiac output, effective orifice area (EOA), and 
degree of aortic insufficiency were determined. A few 
selected patients with small valve sizes underwent cardiac 
catheterization before hospital discharge. Standard labo- 
ratory values, including red blood cell count, leukocyte 
count, hemoglobin concentration, reticulocyte count, and 
serum lactic dehydrogenase, rum alkaline phosphatase, 
haptoglobin, and serum creatinine concentrations were 
obtained at the same time intervals as the echocardio- 
grams. Operative and long-term mortality data were col- 
lected, as well as in-hospital morbidity and complications 
oecurring during the follow-up period. 
Results 
Patient data. Between January 1993 and May 
1994, 64 patients underwent implantation of Free- 
style bioprostheses: 5 size 19 mm, 15 size 21 mm, 16 
size 23 mm, 13 size 25 mm, and 15 size 27 mm valves 
were implanted. Patient demographics and clinical 
parameters are listed in Table I. 
Operative mortality and morbidity. The 30-day 
operative mortality was 3.1% (two patients) (Table 
II). One in-hospital death occurred on the sixth 
postoperative day in a patient being readied for 
hospital discharge. This death occurred suddenly 
and was probably related to an arrhythmia. Autopsy 
revealed coronary atherosclerosis with calcified 
plaques but no evidence of myocardial infarction, 
and the Freestyle valve appeared to be functioning 
normally. One patient died on postoperative day 14 
after hospital discharge. She was readmitted to 
another hospital and treated for bilateral pleural 
etfusions with diuretics. She subsequently became 
hypotensive and died. Postmortem examination re- 
vealed bilateral adrenal hemorrhage and acute sple- 
nitis. No evidence of purulence was noted either in 
the chest cavity or on the valve itself, which ap- 
peared normal. 
Right hemiparesis developed on the second post- 
operative day in one patient, and transient ischemic 
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Table II. Operative r sults 
Patients 
No. % 
Thirty-day mortality 2 3.1 
Stroke 1 1.6 
Transient ischemic attack 2 3.1 
Mediastinitis 2 3.1 
Gastrointestinal bleeding 1 1.6 
Pacemaker 2 3.1 
Table III. Hemodynamic results determined by 
echocardiographic evaluation at the time of 
discharge (óO patients) 
Valve size Gradient (mm Hg) EOA (cm 2) 
19 mm 18.2 (9.0-23.0) 1.0 (0.8-1.3) 
21 mm 13.3 (5.7-25.3) 1.3 (1.0-2.0) 
23 mm 12.2 (4.3-19.3) 1.4 (1.0-1.7) 
25 mm 9.8 (3.2-13.8) 1.7 (1.3-2.4) 
27 mm 10.3 (2.8-21.8) 2.0 (1.1-3.5) 
Gradient, Mean aortic valve gradient; EOA, effective orifice area; range is 
given in parenthesis. 
attacks occurred on the second and fourth postop- 
erative days, respectively, in two patients. In all 
three patients results of computed tomographic 
brain scans were within normal limits. All of these 
neurologic events occurred early in our series when 
we were not routinely administering anticoagulants 
after implantation of the Freestyle bioprosthesis. 
Subsequent to these events all patients have been 
maintained on low-dose anticoagulation with warfa- 
rin sodium, maintaining an international normalized 
ratio of 2.0 to 2.5 for the first 3 months after the 
operation. Since implementing this protocol, we 
have had no further perioperative neurologic events. 
No patient has had an intraoperative neurologic 
injury. 
Two patients required surgical intervention for 
mediastinitis. One patient had significant bleeding 
in the upper gastrointestinal tract from a duodenal 
ulcer on the tenth postoperative day and underwent 
vagotomy and pyloroplasty. Two patients required 
pacemaker insertion before discharge for tachybrady- 
cardia syndrome. 
Posthospitalization data. One patient died 61/2 
months after the operation with no postmortem 
examination. One patient was readmitted 7 months 
after the operation with positive blood cultures for 
Staphylococcus epidermidis and received intravenous 
antibiotic therapy for presumed endocarditis. No 
abnormality of the Freestyle valve was noted by 
Table IV. Hemodynamic results determined by 
postoperative echocardiographic evaluation at 
3 to 6 months (50 patients) 
Valve size Gradient (mm Hg) EOA (cm 2) 
19 mm 18.1 (11.9-22.8) 1.1 (1.0-1.2) 
21 mm 7.2 (3.9-12.3) 1.6 (1.2-2.4) 
23 mm 7.2 (3.1-12.0) 1.7 (1.5-2.2) 
25 mm 5.2 (1.6-10.0) 2.2 (1.6-3.0) 
27 mm 5.5 (1.5-10.7) 2.6 (1.4-4.1) 
Gradient, Mean aortic valve gradient; EOA, effective orifice area; range is 
given in parenthesis. 
Table V. Hemodynamic results determined by 
echocardiographic evaluation at 1-year follow-up 
(nine patients) 
Valve size Gradient (mm Hg) EOA (cm 2) 
19 mm 10.0 (9.0-11.0) 1.5 (1.4-1.6) 
21 mm 6.0 1.6 
23 mm 7.5 (5.0-10.0) 1.8 (1.7-1.8) 
25 mm 8.0 (7.0-9.0) 1.6 (1.4-1.9) 
27 mm 4.0 (2.0-6.0) 2.7 (2.1-3.3) 
Gradient, Mean aortic valve gradient; EOA, effective orifice area; range is 
given in parenthesis. 
echocardiographic evaluation and the patient has 
subsequently done well. Two patients required hos- 
pital admission and blood transfusion for gastroin- 
testinal bleeding 1and 4 months after the operation. 
All but four patients were in New York Heart 
Association class III or IV before the operation, and 
except for one patient, who is still in class III, all 
have improved to class I or II at the most recent 
follow-up visit. 
Hemodynamie data. The mean aortic valve gra- 
dients and EOA for each valve size are listed in 
Table III. Table IV shows the mean gradients and 
the EOA determined by echocardiogram at the 3- to 
6-month follow-up period. EOA increased and 
mean gradient decreased between the two studies. 
The nine patients who have undergone their 1-year 
follow-up echocardiograms (Table V) again show a 
further increase in the EOA and decrease in the 
mean aortic valve gradient. No patient had more 
than trace aortic insuiticiency on any of the fol- 
low-up echocardiograms. Trace aortic valve insuffi- 
ciency was noted in all patients receiving a 19 mm 
valve, one patient receiving a 21 mm, three patients 
receiving a 25 mm, and two patients receiving a 27 
mm prosthesis. 
The echocardiogram ay overestimate he valve 
gradient. Two patients receiving a 19 and a 21 mm 
Freestyle valve underwent cardiac catheterization 
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Table VI. Comparison of Freestyle valve with stented bioprothesis 
Valve area (cm e) 
Series 19 mm 21 mm 23 mm 25 mm 27 mm 
Khan et al. 11 
Carpentier-Edwards* 0.77 0.89 1.14 1.37 1.56 
Hancock* 0.85 1.11 1.59 1.5 1.38 
David et alJ 2 
Hancock II'~ NA 1.18 1.33 1.46 1.55 
Freestyle 
At discharget 1.0 1.3 1.4 1.7 2.0 
At 1 year'~ 1.5 1.6 1.8 1.6 2.7 
Carpentier-Edwards valve, manufactured byBaxter Healthcare Corp., Edwards Division, Santa Ana, Calif. Hancock II valve, manufactured byMedtronic 
Inc., Irvine, Calif. 
*Gorlin area calculated from direct pressure measurements and thermodilution cardiac outputs in the operating room. 
tEffective orifice areas obtained by Doppler echocardiography. 
before hospital discharge. The measured valve gra- 
dients in these patients were less than 5 mm Hg, 
even though in one of these patients the discharge 
gradient by echocardiogram was 25 mm Hg. 
Discussion 
The first clinical implantation of a heterologous 
aortic valve was accomplished by Duran and Gun- 
ning in 1964. 4 Binet and coworkers 4 des¢ribed the 
implantation of five aortic heterografts of both calf 
and pig origin preserved with 2-(ethyl-mercapto- 
mercury) benzoxazol-5 sodium ¢arbonate, and 
O'Brien and Clareborough 5 also used both por¢ine 
and calf aortic valves fixed with 4% buffered forma- 
lin as freehand aortic valve repla¢ements in 23 
patients in 1966. The initial results were excellent 
but the methods of tissue preservation used allowed 
early deterioration. It was not until the introduction 
of glutaraldehyde in 1968 by Alain Carpentier and 
his associates 6 that bioprosthetic valves became 
reasonable alternatives to mechanical prostheses. 
After the commercialization f stented porcine bio- 
prostheses by Hancock Laboratories in the early 
1970s, the further development of the more te¢hni- 
cally demanding stentless bioprostheses sentially 
came to a halt for the next 15 years. Recently, 
interest in glutaraldehyde-fixed nonstented porcine 
aortic valves has been renewed by the promise of 
improved forward flow hemodynamics and the po- 
tential for increased durability over the stented 
porcine bioprosthesis. Siebers and coworkers 7 re- 
ported on the clinical use of a nonstented biopros- 
thesis in 1985. Bernhard and coworkers • developed 
a scalloped, stentless valve supported with a flexible 
cloth-covered ring on the inflow side with the com- 
missures covered with a thin layer of felt. This valve 
was clinicatly implanted for the first time in 1989, 
and in 1991 it was reported to compare favorably 
with allograft valve replacement from the hemody- 
namic standpoint. 9 
David, Ropehan, and Butany 1° began to implant 
an essentially stentless version of the Hancock II 
bioprosthesis in 1987. This valve has fully scalloped 
sinuses and Dacron cloth-covered commissures and 
is sewn to the aortic root by means of a freehand 
technique. They compared 22 patients with the 
stentless valve to an equal number of patients 
undergoing aortic valve replacements with the Han- 
cock II valve. Pressure gradients were significantly 
lower and the EOAs were considerably larger for 
the stentless bioprostheses compared with the 
stented valves. 
The Freestyle aortic root design was based on a 
perceived need to have a readily available alterna- 
tive to the human homograft. Because it is supplied 
as a complete aortic root it may be used for com- 
plete root replacement, implanted by a miniroot 
technique, or inserted freehand within the aortic 
root by scalloping the left and right coronary sinus 
portions or all three coronary sinuses as deemed 
necessary by the implanting surgeon. At present he 
Freestyle valve is not commercially available, but the 
price should be comparable with that of the stented 
modified-orifice Hancock bioprosthesis (personal 
communication from Medtronic Heart Valve, Ir- 
vine, Calif.). 
Our data suggest hat the hemodynamics of the 
stentless Freestyle valve are superior to those of 
stented bioprostheses (Table VI). The surgical tech- 
nique to implant the Freestyle valve is somewhat 
more demanding, necessitating longer crossclamp 
times and attention to detail to achieve acompletely 
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competent valve. Because of the glutaraldehyde 
fixation and Dacron coverage of the muscle bar 
portion of the valve, it is more forgiving than an 
aortic homograft or a pulmonary autograft. Cer- 
tainly any surgeon having experience with insertion 
of aortic homografts should be able to implant he 
Freestyle valve without difficulty. 
Recently, significant discussion has been gener- 
ated regarding the ideal method of implantation for 
homografts, autografts, and stentless bioprostheses. 
If durability of the valve indeed does depend on 
perfect coaptation of the valve leaflets, then im- 
planting all three of these valves as complete roots 
may be the preferred method. Eleven of our patients 
do have trace aortic insufficiency, which has not 
progressed over the short-term follow-up period. 
Further long-term follow-up will be necessary to 
determine if this slight degree of insufficiency leads 
to decreased long-term durability of the valve. 
We believe that several technical aspects are 
important when this stentless bioprosthesis  being 
implanted by means of the freehand technique. The 
valve should not be undersized, because so doing 
may create an outward displacement of the valve 
leaflets preventing them from coapting properly. We 
also believe that the Freestyle valve should not be 
used in large aortic roots, especially when there is a 
discrepancy between the diameter of the sinotubular 
junction and the patient's anulus. In this case im- 
planting the Freestyle valve by a freehand technique 
will result in the commissures being pulled outward 
and prevent coaptation of the valve leaflets, result- 
ing in aortic insulticiency. In these cases either a 
stented bioprosthesis should be used or the Freestyle 
valve should be implanted as a complete aortic root. 
The increase in EOA and decrease in mean aortic 
valve gradients over time with the Freestyle valve has 
been observed by others using stentless porcine bio- 
prostheses. The explanation for this phenomenon is 
not entirely clear, but it may be related to reabsorption 
of the blood or thrombus, which may collect between 
the native aortic wall and the bioprosthesis during the 
early phase after the operation. Certainly we have seen 
flow between the retained noncoronary sinus portion 
of the Freestyle valve and the patient's own aortic wall 
during the intraoperative transesophageal cho studies 
of these patients. 
At present we believe that the Freestyle biopros- 
thesis is the valve of choice in patients requiring 
tissue valves and especially those with small anulus 
sizes. In addition, because the noncoronary sinus 
portion of the Freestyle valve is retained, this tissue 
can be used to enlarge the supravalvular aorta if 
necessary or to reinforce the often very thin aortic 
wall in the area of the aortotomy where it extends 
down into the noncoronary sinus portion of the 
native aorta. In summary, we believe that the stent- 
less bioprosthesis is the valve of choice in the elderly 
patient with a small aortic root. Further long-term 
follow-up is required to determine the durability of 
this valve, although we believe it will last at least as 
long as the stented porcine bioprostheses presently 
available. 
We thank Judy Fletcher, Carla Froelich, and Tim 
Dufrene for their help in the preparation of this manu- 
script. 
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Discussion 
Dr. Roger C. Millar (Sah Lake City, Utah). The search 
goes on for the ideal aortic substitute. It is exciting to use 
the homograft valve freehand techniques to implant the 
glutaraldehyde porcine tissue and to see if the durability 
of the aortic valve can be improved in this older group of 
patients. Ideally, this will provide proof in time to tell us if 
this valve will actually be better than the stented valves. 
We have had limited experience with this same valve, having 
been part of the study since January 1994. We have not been 
anticoagulating our homografts and we have not anticoagu- 
lated our patients with this porcine stentless prosthesis 
either. I noted in your technique that you are including 
Teflon pledgets at all three commissures as part of the 
implantation procedure. We have found this glutaraldehyde- 
treated tissue to be durable and have not thought it neces- 
sary to use prosthetic material, that is, Teflon felt. Do you 
think this is necessary? We worry that part of the reason to 
use this tissue valve is to avoid anticoagulation. You reported 
two cases of significant gastrointestinal bleeding and four 
cases of reexploration for pericardial effusions that possibly 
could be related to the anticoagulation process. Would you 
mind commenting on this? 
Dr. Sintek. We started out not using anticoagulation in 
these patients and then three neurologic events occurred 
early in our series. At that point we decided that we 
should provide low-dose anticoagulation for 3 months. 
We have not been rigid about that. In Very elderly 
patients, in their 80s, who are going to nursing homes or 
who do not have supervision at home, we continue the 
warfarin only for the duration of the hospital stay. There 
has been one transient ischemic attack in the follow-up 
period in one of those patients not receiving warfarin. 
With regard to the pledgets, we have adopted the 
technique of Donald Ross, which is what we use for 
homografts and pulmonary autografts. We are comfort- 
able with the technique. I agree that this valve is rauch 
more forgiving and rauch easier to work with than the 
homograft or certainly the autograft, but we still think that 
the resuspension i commissure is an important part of 
the operation. We have found that the tissue of the 
Freestyle aortic wall itself can be friable. When we did try 
in a couple of cases to not place the pledget, some of the 
stitches cut through the Freestyle valve. We are concerned 
that after the aorta is closed that may allow those com- 
missures to pull down somewhat. 
Dr. Millar. The data you gave on the EOA and the 
major gradients at discharge and 3 months later were 
interesting. You noted no change in the gradient across 
the valves from discharge to 3 months in the 19 mm size 
and virtually no change in the EOA. However, there was 
a decrease of nearly 50% in the gradient and an increase 
in the EOA in both the 21 and 23 mm sizes. Could you 
comment on these data and explain the reason? 
Dr. Sintek. The increase in the EOA and the decrease 
in the aortic valve gradient over time have been observed 
by a couple of other groups implanting stentless valves. 
The explanation for the phenomenon is not entirely clear, 
and why there was a difference in the valve sizes I cannot 
explain. One possible explanation is that, over time, the 
blood or the thrombus that accumulates between the 
Freestyle valve and the patient's aortic wall is reabsorbed. 
During the intraoperative transesophageal echocardio- 
grams of these patients we have seen flow between the 
retained noncoronary sinus portion of the Freestyle valve 
and the patient's aortic wall. Therefore there may be some 
continued flow or thrombus that forms there. Then, over 
the first 6 to 12 months after the operation, that may be 
reabsorbed and lead to a less bulky aortic wall above the 
level of the valve leaflets and therefore a better EOA and 
lower gradient. 
Another possible explanation is that once the valve 
stenosis is relieved, the concentric hypertrophy in the left 
ventricular outflow tract may decrease somewhat. There 
may be some remodeling of the area right beneath the 
anulus. Many of these patients with aortic stenosis have a 
lot of muscle mass, and that may regress lightly with time 
and may provide for better flow characteristics. 
Dr. Bradley J. Harlan (Sacramento, Calif). The attrac- 
tiveness of the hemodynamic advantages are of particular 
interest. I am intrigued that of your 60 patients only 20 
had valves of 21 mm or less. We know that in this age 
group the durability is excellent with the stented biopros- 
thesis. What are your hypothetical advantages in the 
larger valve sizes? 
Dr. Sintek. We agree with you completely. Part of the 
study protocol was that each center would implant 50 of 
these valves. Since fulfilling that obligation, we have 
been implanting these valves only in patients with 19 
and 21 mm anulus sizes or in patients with a 23 mm 
anulus size who have a large body surface area. We see 
no hemodynamic advantage in the size 25 and 27 mm 
valves. There is a longer crossclamp time and that may 
lead to more perioperative complications. We agree 
with you that this valve is best reserved for the patient 
with a small anulus. 
